The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Monoclonal antibodies (mAbs) directed against PD-1/PD-L1 have recently entered the therapeutic algorithm of several solid tumors. Among treatment-related adverse events pulmonary toxicity (PT) is of particular interest. We assess the incidence and relative risk (RR) of PT in patients treated with anti-PD1/PD-L1 mAbs.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Immunotherapy

Title: Immunotherapy

Publisher: Future Medicine Ltd

ISSN (Electronic): 1750-7448

ISSN (Print): 1750-743X

Publication date (Electronic): June 2017

Volume: 9

Issue: 7

Affiliations

[1 ] Department of Medical Oncology, Azienda Ospedaliera Universitaria Integrata (AOUI) Verona, Piazzale L.A. Scuro, 10, 37134 Verona, Italy.

[2 ] Department of Medical Oncology, Azienda Ospedaliera Universitaria Integrata (AOUI), University of Bologna, Italy.

[3 ] Department of Pathology & Diagnostic, Azienda Ospedaliera Universitaria Integrata (AOUI), University of Verona, Piazzale L.A. Scuro, 10, 37134 Verona, Italy.

[4 ] Department of Radiology, Azienda Ospedaliera Universitaria Integrata (AOUI), University of Verona, Piazzale L.A. Scuro, 10, 37134 Verona, Italy.

[5 ] Urologic Clinic, Azienda Ospedaliera Universitaria Integrata (AOUI), University of Verona, Piazzale L.A. Scuro, 10, 37134 Verona, Italy.

Article

DOI: 10.2217/imt-2017-0018

PubMed ID: 28595514

SO-VID: 63fbaec6-1d77-4945-97ec-e86f24cf7579

History

Keywords: nivolumab,pembrolizumab,pulmonary toxicity

Data availability:

Keywords: nivolumab, pembrolizumab, pulmonary toxicity

Comments

Comment on this article

scite_

Cited by 6

See all cited by